Antonina Kuty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Antonina Kuty has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Arkadiusz Kocur
Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
1 shared publication - Bartosz Molasy
Institute of Medical Sciences, Jan Kochanowski University
1 shared publication - Małgorzata Wrzosek
Department of Pharmaceutical Sciences, Collegium Medicum, Jan Kochanowski University, IX Wieków Kielc 19a, 25-516 Kielce, Poland
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (3) , 632
S-Adenosylmethionine (SAM) and S-Adenosylhomocysteine (SAH) Monitoring Using Analytical Methods in Clinical Laboratory Practice: Where Are We?
S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are essential intermediates in one-carbon metabolism and key regulators of cellular methylation capacity. Their concentrations and the SAM/SAH ratio are increasingly studied as biomarkers across metabolic, cardiovascular, neurological, and cancer-related diseases. This review outlines validated analytical methods for quantifying SAM and SAH, focusing primarily on liquid chromatography–tandem mass spectrometry (LC–MS/MS), which is considered the gold standard in both clinical and research settings. A comprehensive literature search identified studies on method development, validation, and clinical use of SAM and SAH measurements. Special attention is given to analytical challenges arising from their high polarity, structural similarity, endogenous presence, and limited stability. The review also discusses preanalytical variables, including biological matrix selection, sample handling, and storage conditions. LC–MS/MS methods are compared with alternative techniques, such as immunoassays, with respect to sensitivity, specificity, matrix effects, and clinical relevance. Additionally, the review summarizes the concentration ranges of SAM and SAH, and their ratio, in healthy and patient populations, noting current standardization limitations. Overall, the review highlights the importance of harmonized analytical protocols and matrix-specific validation to enable reliable clinical interpretation of SAM and SAH as methylation biomarkers.
- 11 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (3) , 632
Open AccessS-Adenosylmethionine (SAM) and S-Adenosylhomocysteine (SAH) Monitoring Using Analytical Methods in Clinical Laboratory Practice: Where Are We?
S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are essential intermediates in one-carbon metabolism and key regulators of cellular methylation capacity. Their concentrations and the SAM/SAH ratio are increasingly studied as biomarkers across metabolic, cardiovascular, neurological, and cancer-related diseases. This review outlines validated analytical methods for quantifying SAM and SAH, focusing primarily on liquid chromatography–tandem mass spectrometry (LC–MS/MS), which is considered the gold standard in both clinical and research settings. A comprehensive literature search identified studies on method development, validation, and clinical use of SAM and SAH measurements. Special attention is given to analytical challenges arising from their high polarity, structural similarity, endogenous presence, and limited stability. The review also discusses preanalytical variables, including biological matrix selection, sample handling, and storage conditions. LC–MS/MS methods are compared with alternative techniques, such as immunoassays, with respect to sensitivity, specificity, matrix effects, and clinical relevance. Additionally, the review summarizes the concentration ranges of SAM and SAH, and their ratio, in healthy and patient populations, noting current standardization limitations. Overall, the review highlights the importance of harmonized analytical protocols and matrix-specific validation to enable reliable clinical interpretation of SAM and SAH as methylation biomarkers.